A small molecule the body already makes may suppress appetite about as strongly as a leading weight-loss drug, at least in animals. Stanford Medicine researchers say it did so without the nausea that often comes with that drug. The molecule is called BRP, and the work is still at the animal stage.
The research was published in Nature in March 2025. It returned to the news this week when ScienceDaily republished Stanford Medicine’s account on 4 November 2026. Headlines have called BRP a “natural Ozempic.” The evidence so far does not support that label, and the researchers have not claimed it does.
How it was found
The team built a computer tool called Peptide Predictor. According to ScienceDaily’s account of the Stanford release, it searched the roughly 20,000 protein-coding genes in the human genome for fragments that might act as hormones. Many hormones begin as larger precursor proteins that are cut into smaller active pieces. Those pieces are hard to spot in the lab.
NewsNation, via KRQE, reported that the tool sorted through more than 2,600 peptide fragments. The researchers then tested candidates on cells. According to a summary of the paper carried by Yahoo, GLP-1 raised the activity of the relevant brain cells. GLP-1 is the hormone that semaglutide, the drug in Ozempic, imitates. A smaller peptide cut from a precursor called BRINP2 did far better. It raised neuronal activity tenfold compared with the control group. That peptide became BRP, short for BRINP2-related peptide.
What happened in the animals
The team tested BRP in lean mice and in minipigs. ScienceDaily notes that minipigs mirror human metabolism and eating patterns more closely than mice do. The animals received an injection into the muscle before feeding.
According to NewsNation, a single dose before a meal cut food intake by up to 50% within an hour. Obese mice given daily injections for two weeks lost about 3 grams on average, almost all of it fat. Untreated mice gained about 3 grams over the same period. The treated mice also showed better glucose and insulin tolerance.
The same report says behavioral tests in mice and pigs showed no differences in movement, water intake, anxious behavior or fecal production. Stanford’s account also says BRP promoted fat loss without the substantial muscle loss that can accompany some weight-reduction treatments.
A different route in the brain
Semaglutide and related drugs act on receptors in several parts of the body. BRP appears to work almost entirely in the hypothalamus, the brain region that governs hunger and metabolism, according to NewsNation. Stanford’s account says this narrower action could eventually help people lose weight without problems such as nausea, constipation or major muscle loss.
The word “eventually” matters. Nausea and diarrhea are common among people taking GLP-1 drugs. NewsNation cited a 2025 RAND Corporation survey of nearly 9,000 US adults in which about half of users reported nausea and about a third reported diarrhea. A drug that avoided those effects would matter to patients. But animals cannot report nausea, and the tests recorded behavior rather than feelings.
What is not known
BRP has not been tested in humans for safety or effectiveness. Psychology Today’s commentary on the work stresses that the evidence is limited to animals. It also notes that BRP is not yet an alternative to Ozempic.
Results in mice and pigs often fail to carry over to people. Dosing, how long the peptide lasts in the body and long-term effects all remain open questions. It is also unclear whether weight loss would continue beyond the two-week mouse experiment.
There is also a commercial interest. Katrin Svensson, the study’s senior author, has cofounded a company to move BRP toward human trials. According to ScienceDaily, she is a cofounder of Merrifield Therapeutics. She and co-author Coassolo are named inventors on patents covering the use of BRP peptides for metabolic disorders. That does not undermine the data, but readers should know about it.
A group of websites selling or promoting peptides has also picked up the story. Anyone seeing BRP offered for sale should know that it is a research-stage discovery, not an approved treatment.
What comes next
The next step is human trials, which the Yahoo summary says the company plans to run. No trial results have been reported in the sources reviewed here. Until there are, BRP remains a promising lead from a new search method. The method itself may matter as much as the molecule. Peptide Predictor could be used on other hormone-like fragments hidden in the genome, in obesity research and elsewhere.
